<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GENTAVED - gentamicin sulfate and betamethasone valerate solution </strong><br>Vedco<br></p></div>
<h1>GentaVed Otic Solution</h1>
<div class="Contents">
<div class="Section" data-sectionCode="34089-3">
<a name="e6cc5c5c-cafd-431b-8f20-fd7a8f7272d3"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">GENTAMICIN SULFATE with BETAMETHASONE VALERATE OTIC SOLUTION</span></p>
<p><span class="Bold">ANADA #200-183, Approved by FDA<br>For Use in Dogs and Cat Only.</span></p>
<p><span class="Bold"><span class="Underline">CAUTION:</span><span class="Bold"><span class="Bold"> Federal law restricts this drug to use by or on the order of a licensed veterinarian.</span></span></span></p>
<p><span class="Underline">DESCRIPTION:</span>  Gentamicin Sulfate with Betamethasone Valerate Otic Solution is packaged in a convenient plastic squeeze bottle for easy application.  Each mL of Gentamicin Sulfate with Betamethasone Valerate Otic Solution contains gentamicin sulfate equivalent to 3 mg gentamicin base, betamethasone valerate equivalent to 1 mg betamethasone, 1.0 mg hydroxyethylcellulose, 2.5 mg glacial acetic acid, 200 mg purified water, 19% ethanol, 9.4 mg benzyl alcohol as preservative, 300 mg glycerin and propylene glycol q.s.<br><br><span class="Underline">CHEMISTRY:</span> Gentamicin is a bactericidal antibiotic of the aminoglycoside group derived from <span class="Italics">Micromonospora</span>  <span class="Italics">purpurea</span> of the <span class="Italics">Actinomyces</span>  group. It is a powder, white to buff in color, basic in nature, readily soluble in water and highly stable in solution.</p>
<p>Betamethasone valerate is a synthetic corticosteroid derivative of prednisolone.<br></p>
<p><span class="Underline">ACTION:</span> Gentamicin Sulfate with Betamethasone Valerate Otic Solution combines the broad-spectrum activity of gentamicin sulfate with the anti-inflammatory and antipruritic activity of betamethasone valerate. <span class="Italics">In vitro</span> antibacterial activity<span class="Sup">1</span> has shown that gentamicin is active against most gram-negative bacteria including <span class="Italics">Pseudomonas</span><span class="Italics"> aeruginosa</span>, indole-positive and negative <span class="Italics">proteus</span><span class="Italics"> sp</span>., <span class="Italics">Escherichia</span><span class="Italics"> coli</span>, <span class="Italics">Klebsiella</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span>e, <span class="Italics">Aerobacter</span><span class="Italics"> aerogenes</span>, and <span class="Italics">Neisseria</span>. Gentamicin is also active against <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of gram-positive bacteria including <span class="Italics">Staphylococcus</span> species and some <span class="Italics">Streptococcus</span> species.<br></p>
<p>Betamethasone valerate has emerged from intensive research as the most promising of some 50 newly synthesized corticosteroids in the experimental model described by McKenzie<span class="Sup">2</span> et al. This human bioassay technique has been found reliable for evaluating the vasoconstrictor properties of new topical corticosteroids and is useful in predicting clinical efficacy.</p>
<p>Betamethasone valerate in human medicine has been shown to provide anti-inflammatory and antipruritic activity in the topical management of corticosteroid-responsive dermatoses. In the responsive cases, the local anti-inflammatory activity is sustained by the vasoconstrictor properties of the steroid.  <br></p>
<p><span class="Underline">TOXICITY STUDIES:</span> Parenterally, no toxic effects were observed in rats given gentamicin sulfate 20 mg/kg/day for twenty-four days; in cats given 10 mg/kg/day for forty days. Gentamicin sulfate given to dogs at 6 mg/lb/day, 6 days weekly for three weeks, caused no detectable kidney damage. At higher doses, impairment of equilibrium and of renal function were observed in these species.</p>
<p>Subacute otic toxicity study in dogs showed gentamicin sulfate with betamethasone valerate solution to be well tolerated locally with no adverse systemic effects when administered 5 drops twice a day for 21 consecutive days.</p>
<p>Gentamicin sulfate solution in a 21-day subacute dermal toxicity study in dogs was shown to be well tolerated when applied topically to abraded skin. There were no meaningful findings except a reduction in eosinophil count attributable to absorption of the corticosteroid component. <br><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b7e99f15-4e8d-4ad6-bd68-a44c9abcd278"></a><a name="section-2"></a><p></p>
<p class="First"><span class="Underline">INDICATIONS:</span> Gentamicin Sulfate with Betamethasone Valerate Otic Solution is indicated for the treatment of acute and chronic canine <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b601b668-1bf4-424d-bc48-7c68828d6e25"></a><a name="section-3"></a><p></p>
<p class="First"><span class="Underline">DOSAGE AND ADMINISTRATION:</span> Duration of treatment will depend upon the severity of the condition and the response obtained. The duration of treatment and/or frequency of the dosage may be reduced, but care should be taken not to discontinue therapy prematurely.</p>
<p><span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">Otitis externa</span> – The external ear and ear canal should be properly cleaned and dried before treatment. Remove foreign material, debris, crusted exudates, etc., with suitable nonirritating solution. Excessive hair should be clipped from the treatment area of the external ear. Instill 3 to 8 drops of Gentamicin Sulfate with Betamethasone Valerate Otic Solution (approximately room temperature) into the ear canal twice daily for seven to fourteen days.</p>
<p>Superficial infected lesions – The lesion and adjacent area should be properly cleaned before treatment. Excessive hair should be removed. Apply a sufficient amount of Gentamicin Sulfate with Betamethasone Valerate Otic Solution to cover the treatment area twice daily seven to fourteen days.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="be2704df-20f0-476e-8a00-6c0377bc28cf"></a><a name="section-4"></a><p></p>
<p class="First"><span class="Underline">CONTRAINDICATIONS:</span> If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted.</p>
<p>Concomitant use of drugs known to induce <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> should be avoided.</p>
<p>This preparation should not be used in conditions where corticosteroids are contraindicated.</p>
<p>Do not administer parenteral corticosteroids during treatment with Gentamicin Sulfate with Betamethasone Valerate Otic Solution.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b28157ff-11fc-4361-a4d3-bdd778199200"></a><a name="section-5"></a><p></p>
<p class="First"><span class="Underline">PRECAUTIONS:</span> The antibiotic sensitivity of the pathogenic organism should be determined prior to the use of this preparation. Use of topical antibiotics occasionally allows overgrowth of non-susceptible bacteria, fungi or yeasts. If these cases, treatment should be instituted with other appropriate agents as indicated.</p>
<p>Adverse systemic reactions have been observed following the oral ingestion of some topical corticosteroid preparations. Patients should be closely observed for the usual signs of adrenocorticosteroid overdosage, which include <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> and/or <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>. Prolonged use or overdosage may produce adverse immunosuppressive effects.</p>
<p>Experimentally it has been demonstrated that corticosteroids, especially at high dosage levels, may result in delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. An increase in the incidence of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> may be noted, mainly in the elderly, with prolonged use of these compounds.  Their use in older dogs during the healing stages of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in not indicated for the reason listed above.</p>
<p>Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations.</p>
<p><span class="Underline">CAUTIONS:</span> Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membrane is not ruptured in order to avoid the possibility of transmitting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to the middle ear as well as damaging the cochlea or vestibular apparatus from prolonged contact.  If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of Gentamicin Sulfate with Betamethasone Valerate Otic Solution.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="e6a9983e-00ce-4b40-8f45-c7095b979b22"></a><a name="section-6"></a><p></p>
<p class="First"><span class="Underline">WARNING:</span> Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span> and metritis. Additionally, corticosteroids can induce <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palates</span> in offspring when given to pregnant animals during the period of palate closure of the embryos. Other congenital anomalies, including deformed forelegs, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">phocomelia</span> and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span>, have been reported in offspring of dogs which received corticosteroids during pregnancy.</p>
<p>Avoid ingestion.<br><br><span class="Underline">SIDE EFFECTS:</span> Side effects such as SAP and SGPT enzyme elevations, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> have occurred following the use of parenteral or systemic synthetic corticosteroids in dogs. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occasionally bloody) have been observed in dogs and cats. Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a5c0096f-c444-4487-a675-c100e26674a0"></a><a name="section-7"></a><p></p>
<p class="First"><span class="Underline">HOW SUPPLIED:</span> Gentamicin Sulfate with Betamethasone Valerate Otic Solution, squeeze bottles of 7.5 mL, 15 mL and 240 mL (8 fl. Oz.).</p>
<p>Store between 2°C and 25°C (36°F and 77°F).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-8"></a><p></p>
<p class="First"><span class="Underline">REFERENCES:</span><br>1. Weinstein, M.J., Leudemann, G.M., Oden, E.M., and Wagman, G.H.: Gentamicin, a new broad-spectrum antibiotic complex. Antimicrobial Agents and Chemotherapy, 1963, pp 1-7.</p>
<p>2. McKenzie, A.W., and Atkinson, R.M. Topical activities of betamethasone esters in man. Arch Derm. 1964; 19:741-746.<br></p>
<p>May 1996<br>Manufactured by <br>Med-Pharmex, Inc<br>Pomona, CA 91767</p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-9"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-9"></a><p></p>
<p class="First"><img alt="GentaVed 7.5 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=067aff1c-0876-414d-8aa4-7b214f4d5a8e&amp;name=GentaVed%207.5%20mL.jpg"><br></p>
<p><img alt="GentaVed 15 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=067aff1c-0876-414d-8aa4-7b214f4d5a8e&amp;name=GentaVed%2015%20mL.jpg"><br></p>
<p><img alt="GentaVed 240 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=067aff1c-0876-414d-8aa4-7b214f4d5a8e&amp;name=GentaVed%20240%20mL.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GENTAVED 		
					</strong><br><span class="contentTableReg">gentamicin sulfate with betamethasone valerate  solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50989-460</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">AURICULAR (OTIC)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GENTAMICIN SULFATE</strong> (GENTAMICIN) </td>
<td class="formItem">GENTAMICIN</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BETAMETHASONE VALERATE</strong> (BETAMETHASONE ) </td>
<td class="formItem">BETAMETHASONE </td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50989-460-66</td>
<td class="formItem">7.5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50989-460-08</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:50989-460-74</td>
<td class="formItem">240 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANADA</td>
<td class="formItem">ANADA200183</td>
<td class="formItem">05/01/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Vedco
							(021634266)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Med-Pharmex, Inc (025353699)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Med-Pharmex, Inc</td>
<td class="formItem"></td>
<td class="formItem">025353699</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/1996<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>168b2601-8d9d-4417-a3b2-d286ea4d93e2</div>
<div>Set id: 067aff1c-0876-414d-8aa4-7b214f4d5a8e</div>
<div>Version: 1</div>
<div>Effective Time: 19960501</div>
</div>
</div> <div class="DistributorName">Vedco</div></p>
</body></html>
